The influence of chemokine receptor CCR2 genotypes in the route to cervical carcinogenesis

Gynecologic and Obstetric Investigation

Volumn 64, Issue 4, 2007, Pages 208-212

  Coelho, Ana ^a   Matos, Ana ^a   Catarino, Raquel ^a   Pinto, Daniela ^a   Sousa, Hugo ^a   Pereira, Deolinda ^a   Medeiros, Rui ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

CCL2; CCR2; Cervical cancer; Chemokines; High grade squamous intraepithelial lesions; Human papillomavius; Immunology; Low grade squamous intraepithelial lesions; Polymorphism

Indexed keywords

CHEMOKINE RECEPTOR CCR2;

ADULT; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CASE CONTROL STUDY; CONDYLOMA; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UTERINE CERVIX CARCINOMA;

ADULT; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PORTUGAL; RECEPTORS, CCR2; UTERINE CERVICAL NEOPLASMS;

EID: 36048932962     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106492     Document Type: Article

References (25)

1. Franco EL, Schlecht NF, Saslow D: The epidemiology of cervical cancer. Cancer J 2003;9:348-359.
2. Matos A, Moutinho J, Pinto D, Medeiros R: The influence of smoking and other cofactors on the time to onset to cervical cancer in a southern European population. Eur J Cancer Prev 2005;14:485-491.
3. Medeiros R, Prazeres H, Pinto D, Macedo-Pinto I, Lacerda M, Lopes C, Cruz E: Characterization of HPV genotype profile in squamous cervical lesions in Portugal, a southern European population at high risk of cervical cancer. Eur J Cancer Prev 2005;14:467-471.
4. Craveiro R, Costa S, Pinto D, Salgado L, Carvalho L, Castro C, Bravo I, Lopes C, Silva I, Medeiros R: TP73 alterations in cervical carcinoma. Cancer Genet Cytogenet 2004;150:116-121.
5. Rohan TE, Burk RD, Franco EL: Toward a reduction of the global burden of cervical cancer. Am J Obstet Gynecol 2003;189:S37-S39.
6. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ: HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-164.
7. Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M, Levine AM, Darragh TM, Weinberg V, Smith-McCune KK: Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004;64:6766-6774.
8. Tindle RW: Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002;2:59-65.
9. Nguyen HH, Broker TR, Chow LT, Alvarez RD, Vu HL, Andrasi J, Brewer LR, Jin G, Mestecky J: Immune responses to human papillomavirus in genital tract of women with cervical cancer. Gynecol Oncol 2005;96:452-461.
10. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-350.
11. Gerard C, Rollins BJ: Chemokines and disease. Nat Immunol 2001;2:108-115.
12. Kleine-Lowinski K, Gillitzer R, Kuhne-Heid R, Rosl F: Monocyte-chemo-attractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas. Int J Cancer 1999;82:6-11.
13. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254-265.
14. Vicari AP, Caux C: Chemokines in cancer. Cytokine Growth Factor Rev 2002;13:143-154.
15. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L: The origin and function of tumor-associated macrophages. Immunol Today 1992;13:265-270.
16. Coelho A, Matos A, Catarino R, Pinto D, Pereira D, Lopes C, Medeiros R: Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol 2005;96:760-764.
17. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
18. Kristiansen TB, Knudsen TB, Ohlendorff S, Eugen-Olsen J: A new multiplex PCR strategy for the simultaneous determination of four genetic polymorphisms affecting HIV-1 disease progression. J Immunol Methods 2001;252:147-151.
19. Riethdorf L, Riethdorf S, Gutzlaff K, Prall F, Loning T: Differential expression of the monocyte chemoattractant protein-1 gene in human papillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri. Am J Pathol 1996;149:1469-1476.
20. Kleine-Lowinski K, Rheinwald JG, Fichorova RN, Anderson DJ, Basile J, Munger K, Daly CM, Rosl F, Rollins BJ: Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer 2003;107:407-415.
21. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-686.
22. Sica A, Schioppa T, Mantovani A, Allavena P: Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717-727.
23. Woodworth CD: HPV innate immunity. Front Biosci 2002;7:d2058-d2071.
24. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T: A CCR2-V64I polymorphism affects stability of CCR2A isoform. Aids 2004;18:729-738.
25. Sanders SK, Crean SM, Boxer PA, Kellner D, LaRosa GJ, Hunt SW 3rd: Functional differences between monocyte chemotactic protein-1 receptor A and monocyte chemotactic protein-1 receptor B expressed in a Jurkat T cell. J Immunol 2000;165:4877-4883.